Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

• Status: Not yet recruiting
• Trial end date: 2025-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer.

Participants will:

• Complete two phases involving 6 visits

• Undergo additional research PET/CT, and possibly SPECT/CT scans

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Lutetium Lu 177 dotatate

Criteria

Inclusion Criteria:

• Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor

Exclusion Criteria:

• Unable to lie flat during or tolerate PET/CT or SPECT/CT

• Known incompatibility to CT. SPECT, or PET scans

• Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study